Rubeli: Lofty prices plague opportunities

Inflated valuations for target companies means GPs have to be increasingly selective in their investments, says Partners Group’s Christoph Rubeli.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this